ReShape Lifesciences reported a modest quarterly revenue rebound in Q3 2024, with revenue of 2.29 million, up 6% year over year and 16.6% sequentially from Q2. The quarter benefited from a higher gross margin (62.8% vs. prior-year 60%), driven by ongoing cost reductions that contributed to a 41% year-to-date reduction in operating expenses through nine months. Management highlighted progress on growth drivers, including the commercial launch of Lap-Band 2.0 FLEX and regulatory progress (Health Canada approval) as well as non-dilutive NIH funding for the DBSN program, underscoring a strategic pivot toward higher-margin growth initiatives while preserving liquidity. In parallel, the company advanced strategic optionality via a merger with Vyome Therapeutics and an accompanying asset sale to Biorad, designed to unlock shareholder value and provide a platform for scale in a broader healthcare technology ecosystem. NASDAQ compliance was regained in October after a 1-for-58 reverse stock split, a prerequisite for the Vyome transaction. On the downside, RSLS continues to operate with net losses and a negative EBITDA in the near term, and cash remains limited (cash end of period approximately $0.843 million). The upcoming catalysts include continued Lap-Band 2.0 FLEX commercialization, regulatory approvals, NIH-funded DBSN development outcomes, and the Vyome/Vyome-go-forward strategy close to completion. Investors should monitor operating cash burn, regulatory milestones across jurisdictions, integration risk of the Vyome transaction, and the pace of adoption among obesity-treatment pathways as GLP-1 therapies influence the competitive landscape.